

# Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Rhabdoid Tumors

Cancer Cell

30, 891-908

DOI: [10.1016/j.ccell.2016.11.003](https://doi.org/10.1016/j.ccell.2016.11.003)

Citation Report

#	ARTICLE	IF	CITATIONS
1	PGBD5 promotes site-specific oncogenic mutations in human tumors. <i>Nature Genetics</i> , 2017, 49, 1005-1014.	9.4	69
2	Sellar Atypical Teratoid/Rhabdoid Tumor (AT/RT). <i>American Journal of Surgical Pathology</i> , 2017, 41, 932-940.	2.1	38
3	Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot. <i>European Journal of Pediatrics</i> , 2017, 176, 1163-1172.	1.3	11
4	High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid Tumors. <i>Cell Reports</i> , 2017, 21, 1737-1745.	2.9	32
5	Integrating RNA sequencing into neuro-oncology practice. <i>Translational Research</i> , 2017, 189, 93-104.	2.2	10
6	SWI/SNF-Komplex-assoziierte Tumordispositions-Syndrome. <i>Medizinische Genetik</i> , 2017, 29, 296-305.	0.1	3
8	Genomic Analysis of Childhood Brain Tumors: Methods for Genome-Wide Discovery and Precision Medicine Become Mainstream. <i>Journal of Clinical Oncology</i> , 2017, 35, 2346-2354.	0.8	25
9	Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics. <i>Advances in Anatomic Pathology</i> , 2018, 25, 143-171.	2.4	31
10	Fitting the epigenome into the picture: methylation classification for paediatric brain tumours. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 543-547.	1.8	0
11	Primary diffuse leptomeningeal atypical teratoid/rhabdoid tumor diagnosed by cerebrospinal fluid cytology: case report with molecular genetic analysis. <i>Human Pathology</i> , 2018, 77, 116-120.	1.1	7
12	Sellar Region Atypical Teratoid/Rhabdoid Tumors (ATRT) in Adults Display DNA Methylation Profiles of the ATRT-MYC Subgroup. <i>American Journal of Surgical Pathology</i> , 2018, 42, 506-511.	2.1	43
13	Emerging therapeutic targets for the treatment of malignant rhabdoid tumors. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 365-379.	1.5	46
14	<scp>CNS</scp> embryonal tumours: <scp>WHO</scp> 2016 and beyond. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 151-162.	1.8	33
15	Improving Diagnostic and Therapeutic Outcomes in Pediatric Brain Tumors. <i>Molecular Diagnosis and Therapy</i> , 2018, 22, 25-39.	1.6	8
16	Review of molecular classification and treatment implications of pediatric brain tumors. <i>Current Opinion in Pediatrics</i> , 2018, 30, 3-9.	1.0	38
17	Malignant Brain Tumours in Children : Present and Future Perspectives. <i>Journal of Korean Neurosurgical Society</i> , 2018, 61, 402-406.	0.5	3
18	Rare Embryonal Brain Tumours. , 2018, , 289-316.		5
19	Advances in the classification of pediatric brain tumors through DNA methylation profiling: From research tool to frontline diagnostic. <i>Cancer</i> , 2018, 124, 4168-4180.	2.0	64

#	ARTICLE	IF	CITATIONS
20	Sellar Region Atypical Teratoid/Rhabdoid Tumors in Adults: Clinicopathological Characterization of Five Cases and Review of the Literature. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 1115-1121.	0.9	21
21	A biobank of patient-derived pediatric brain tumor models. <i>Nature Medicine</i> , 2018, 24, 1752-1761.	15.2	124
22	Magnetic resonance imaging surrogates of molecular subgroups in atypical teratoid/rhabdoid tumor. <i>Neuro-Oncology</i> , 2018, 20, 1672-1679.	0.6	40
23	Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy. <i>Cancer Discovery</i> , 2018, 8, 1376-1389.	7.7	40
24	Cerebellar tumors. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 155, 289-299.	1.0	8
25	Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours. <i>Nature Reviews Cancer</i> , 2019, 19, 420-438.	12.8	98
26	A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. <i>Cancer Cell</i> , 2019, 36, 51-67.e7.	7.7	69
27	Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration. <i>Cell Reports</i> , 2019, 29, 2338-2354.e7.	2.9	74
28	Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors. <i>Cancer Cell</i> , 2019, 36, 597-612.e8.	7.7	100
29	Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors. <i>Cell Reports</i> , 2019, 28, 2331-2344.e8.	2.9	24
30	NPM1 as a potential therapeutic target for atypical teratoid/rhabdoid tumors. <i>BMC Cancer</i> , 2019, 19, 848.	1.1	13
31	Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine. <i>Clinical Cancer Research</i> , 2019, 25, 5925-5936.	3.2	22
32	Dangerous liaisons: interplay between SWI/SNF, NuRD, and Polycomb in chromatin regulation and cancer. <i>Genes and Development</i> , 2019, 33, 936-959.	2.7	127
33	Atypical Teratoid Rhabdoid Tumors. , 2019, , 615-629.		0
34	Molecular pathology of tumors of the central nervous system. <i>Annals of Oncology</i> , 2019, 30, 1265-1278.	0.6	129
35	Tumor Mesenchymal Stromal Cells Regulate Cell Migration of Atypical Teratoid Rhabdoid Tumor through Exosome-Mediated miR155/SMARCA4 Pathway. <i>Cancers</i> , 2019, 11, 720.	1.7	21
36	GenPipes: an open-source framework for distributed and scalable genomic analyses. <i>GigaScience</i> , 2019, 8, .	3.3	121
37	Atypical Teratoid/Rhabdoid Sellar Tumor in an Adult with a Familial History of a Germline SMARCB1 Mutation: Case Report and Review of the Literature. <i>World Neurosurgery</i> , 2019, 127, 336-345.	0.7	12

#	ARTICLE	IF	CITATIONS
38	Evaluation of Protein Kinase Inhibitors with PLK4 Cross-Over Potential in a Pre-Clinical Model of Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2112.	1.8	33
39	Two molecularly distinct atypical teratoid/rhabdoid tumors (or tumor components) occurring in an infant with rhabdoid tumor predisposition syndrome 1. <i>Acta Neuropathologica</i> , 2019, 137, 847-850.	3.9	7
40	Pediatric Atypical Teratoid/Rhabdoid Tumors of the Brain: Identification of Metabolic Subgroups Using In Vivo <sup>1</sup> H-MR Spectroscopy. <i>American Journal of Neuroradiology</i> , 2019, 40, 872-877.	1.2	6
41	p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. <i>Cancer Cell</i> , 2019, 35, 204-220.e9.	7.7	62
42	Stalled developmental programs at the root of pediatric brain tumors. <i>Nature Genetics</i> , 2019, 51, 1702-1713.	9.4	136
43	Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo. <i>International Journal of Cancer</i> , 2019, 144, 1983-1995.	2.3	43
44	Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation. <i>Cancer Cell</i> , 2019, 35, 95-110.e8.	7.7	65
45	Functional relevance of genes predicted to be affected by epigenetic alterations in atypical teratoid/rhabdoid tumors. <i>Journal of Neuro-Oncology</i> , 2019, 141, 43-55.	1.4	7
46	Prognostic and Predictive Epigenetic Biomarkers in Oncology. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 83-95.	1.6	57
47	Case-based review: atypical teratoid/rhabdoid tumor. <i>Neuro-Oncology Practice</i> , 2019, 6, 163-178.	1.0	18
48	Tyrosinase immunohistochemistry can be employed for the diagnosis of atypical teratoid/rhabdoid tumours of the tyrosinase subgroup (ATRT-TYR). <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 186-189.	1.8	9
49	Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers. <i>Seminars in Cancer Biology</i> , 2020, 61, 180-198.	4.3	28
50	Subgroup-specific outcomes of children with malignant childhood brain tumors treated with an irradiation-sparing protocol. <i>Child's Nervous System</i> , 2020, 36, 133-144.	0.6	3
51	MEK/MELK inhibition and blood-brain barrier deficiencies in atypical teratoid/rhabdoid tumors. <i>Neuro-Oncology</i> , 2020, 22, 58-69.	0.6	21
52	Secondary INI1-deficient rhabdoid tumors of the central nervous system: analysis of four cases and literature review. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 763-772.	1.4	8
53	Targeting MEK/MELK in atypical teratoid rhabdoid tumor: a treatment approach aimed at exploiting blood-brain barrier deficiencies. <i>Neuro-Oncology</i> , 2020, 22, 3-4.	0.6	3
54	Translational genomics of malignant rhabdoid tumours: Current impact and future possibilities. <i>Seminars in Cancer Biology</i> , 2020, 61, 30-41.	4.3	17
55	Pediatric embryonal brain tumors in the molecular era. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 293-303.	1.5	6

#	ARTICLE	IF	CITATIONS
56	SWI/SNF complex heterogeneity is related to polyphenotypic differentiation, prognosis, and immune response in rhabdoid tumors. <i>Neuro-Oncology</i> , 2020, 22, 785-796.	0.6	18
57	Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors. <i>Neuro-Oncology</i> , 2020, 22, 1006-1017.	0.6	72
58	Outcomes with respect to extent of surgical resection for pediatric atypical teratoid rhabdoid tumors. <i>Child's Nervous System</i> , 2020, 36, 713-719.	0.6	10
59	Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults. <i>Acta Neuropathologica</i> , 2020, 139, 277-286.	3.9	36
60	Cancer of the Central Nervous System. , 2020, , 906-967.e12.		9
61	Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. <i>Acta Neuropathologica</i> , 2020, 139, 259-271.	3.9	36
62	Macrophage-tumor cell interaction promotes ATRT progression and chemoresistance. <i>Acta Neuropathologica</i> , 2020, 139, 913-936.	3.9	24
63	Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. <i>Acta Neuropathologica</i> , 2020, 139, 223-241.	3.9	65
64	Principles and methods of integrative chromatin analysis in primary tissues and tumors. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1873, 188333.	3.3	7
65	Molecular subgrouping of atypical teratoid/rhabdoid tumors—a reinvestigation and current consensus. <i>Neuro-Oncology</i> , 2020, 22, 613-624.	0.6	133
66	Embryonal tumors of the central nervous system. <i>Current Opinion in Oncology</i> , 2020, 32, 623-630.	1.1	5
67	Atypical teratoid rhabdoid tumor: molecular insights and translation to novel therapeutics. <i>Journal of Neuro-Oncology</i> , 2020, 150, 47-56.	1.4	30
68	Proteasome inhibition as a therapeutic approach in atypical teratoid/rhabdoid tumors. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa051.	0.4	8
69	Histopathologic and Molecular Features of Central Nervous System Embryonal Tumors for Integrated Diagnosis Reporting. <i>Surgical Pathology Clinics</i> , 2020, 13, 783-800.	0.7	1
71	Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity. <i>Nature Communications</i> , 2020, 11, 4324.	5.8	75
72	CAR T Cell Therapy for Pediatric Brain Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 1582.	1.3	37
73	SMARCB1 loss interacts with neuronal differentiation state to block maturation and impact cell stability. <i>Genes and Development</i> , 2020, 34, 1316-1329.	2.7	30
74	MEK Inhibition Suppresses Growth of Atypical Teratoid/Rhabdoid Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 746-753.	0.9	4

#	ARTICLE	IF	CITATIONS
75	Patient-derived orthotopic xenografts of pediatric brain tumors: a St. Jude resource. <i>Acta Neuropathologica</i> , 2020, 140, 209-225.	3.9	45
76	<scp>SMARCB1</scp> loss induces druggable cyclin <scp>D1</scp> deficiency via upregulation of <scp><i>MIR17HG</i></scp> in atypical teratoid rhabdoid tumors. <i>Journal of Pathology</i> , 2020, 252, 77-87.	2.1	11
77	Clinical characteristics, treatment, and survival outcome in pediatric patients with atypical teratoid/rhabdoid tumors: a retrospective study by the Japan Childrenâ€™s Cancer Group. <i>Journal of Neurosurgery: Pediatrics</i> , 2020, 25, 111-120.	0.8	16
78	Analysis of Dual Class I Histone Deacetylase and Lysine Demethylase Inhibitor Domatinostat (4SC-202) on Growth and Cellular and Genomic Landscape of Atypical Teratoid/Rhabdoid. <i>Cancers</i> , 2020, 12, 756.	1.7	25
79	Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumors. <i>Neuro-Oncology</i> , 2020, 22, 944-954.	0.6	25
80	A lncRNA-SWI/SNF complex crosstalk controls transcriptional activation at specific promoter regions. <i>Nature Communications</i> , 2020, 11, 936.	5.8	69
81	Efficacy of High-Dose Chemotherapy and Three-Dimensional Conformal Radiation for Atypical Teratoid/Rhabdoid Tumor: A Report From the Childrenâ€™s Oncology Group Trial ACNS0333. <i>Journal of Clinical Oncology</i> , 2020, 38, 1175-1185.	0.8	102
82	Invited Review: DNA methylationâ€™based classification of paediatric brain tumours. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 28-47.	1.8	33
83	SWI/SNF complex differences promote cellular heterogeneity in rhabdoid tumors. <i>Neuro-Oncology</i> , 2020, 22, 741-742.	0.6	1
84	Upregulation of Protein Synthesis and Proteasome Degradation Confers Sensitivity to Proteasome Inhibitor Bortezomib in Myc-Atypical Teratoid/Rhabdoid Tumors. <i>Cancers</i> , 2020, 12, 752.	1.7	6
85	Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. <i>Nature Medicine</i> , 2020, 26, 712-719.	15.2	172
86	The SWI/SNF complex in cancer â€™ biology, biomarkers and therapy. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 435-448.	12.5	297
87	Invited Review: Dysregulation of chromatin remodellers in paediatric brain tumours â€™ SMARCB1 and beyond. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 57-72.	1.8	10
89	Drug screening with a novel tumor-derived cell line identified alternative therapeutic options for patients with atypical teratoid/rhabdoid tumor. <i>Human Cell</i> , 2021, 34, 271-278.	1.2	2
90	Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases. <i>Acta Neuropathologica</i> , 2021, 141, 291-301.	3.9	47
91	Understanding the trajectory of research efforts in atypical teratoid rhabdoid tumors: a bibliometric analysis of the 50 most impactful studies to date. <i>Child's Nervous System</i> , 2021, 37, 419-425.	0.6	3
92	An Adult Case of Sellar Atypical Teratoid/Rhabdoid Tumor Presenting with Lung Metastasis, Harboring a Compound Heterozygous Mutation in INI1. <i>NMC Case Report Journal</i> , 2021, 8, 267-274.	0.2	2
93	DNA methylation profiling as a model for discovery and precision diagnostics in neuro-oncology. <i>Neuro-Oncology</i> , 2021, 23, S16-S29.	0.6	34

#	ARTICLE	IF	CITATIONS
94	DIMEimmune: Robust estimation of infiltrating lymphocytes in CNS tumors from DNA methylation profiles. <i>OncImmunity</i> , 2021, 10, 1932365.	2.1	17
95	Rhabdoid Tumor Predisposition Syndrome: From Clinical Suspicion to General Management. <i>Frontiers in Oncology</i> , 2021, 11, 586288.	1.3	20
96	Neonatal Central Nervous System Tumors. <i>Clinics in Perinatology</i> , 2021, 48, 35-51.	0.8	3
97	Recent Advances in Understanding the Role of Autophagy in Paediatric Brain Tumours. <i>Diagnostics</i> , 2021, 11, 481.	1.3	5
98	Somatic mutations and single-cell transcriptomes reveal the root of malignant rhabdoid tumours. <i>Nature Communications</i> , 2021, 12, 1407.	5.8	41
99	Histopathological patterns in atypical teratoid/rhabdoid tumors are related to molecular subgroup. <i>Brain Pathology</i> , 2021, 31, e12967.	2.1	16
100	Inhibition of nuclear export restores nuclear localization and residual tumor suppressor function of truncated SMARCB1/INI1 protein in a molecular subset of atypical teratoid/rhabdoid tumors. <i>Acta Neuropathologica</i> , 2021, 142, 361-374.	3.9	6
101	SMARCB1 deletion in atypical teratoid rhabdoid tumors results in human endogenous retrovirus K (HML-2) expression. <i>Scientific Reports</i> , 2021, 11, 12893.	1.6	17
102	Optical genome mapping identifies a germline retrotransposon insertion in <i>SMARCB1</i> in two siblings with atypical teratoid rhabdoid tumors. <i>Journal of Pathology</i> , 2021, 255, 202-211.	2.1	23
103	Pathogenic noncoding variants in the neurofibromatosis and schwannomatosis predisposition genes. <i>Human Mutation</i> , 2021, 42, 1187-1207.	1.1	5
104	Haplotype-resolved germline and somatic alterations in renal medullary carcinomas. <i>Genome Medicine</i> , 2021, 13, 114.	3.6	5
105	Combination Treatment of CI-994 With Etoposide Potentiates Anticancer Effects Through a Topoisomerase II-Dependent Mechanism in Atypical Teratoid/Rhabdoid Tumor (AT/RT). <i>Frontiers in Oncology</i> , 2021, 11, 648023.	1.3	2
106	Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29267.	0.8	7
107	Recent Advances in Pediatric Cancer Research. <i>Cancer Research</i> , 2021, 81, 5783-5799.	0.4	8
108	Polycomb repressive complex 2 in the driver's seat of childhood and young adult brain tumours. <i>Trends in Cell Biology</i> , 2021, 31, 814-828.	3.6	17
109	Pioneer factors in development and cancer. <i>iScience</i> , 2021, 24, 103132.	1.9	15
110	Chromatin accessibility profiling methods. <i>Nature Reviews Methods Primers</i> , 2021, 1, .	11.8	95
113	Advances in the classification and treatment of pediatric brain tumors. <i>Current Opinion in Pediatrics</i> , 2021, 33, 26-32.	1.0	11

#	ARTICLE	IF	CITATIONS
115	Pediatric Brain Tumors. CONTINUUM Lifelong Learning in Neurology, 2017, 23, 1727-1757.	0.4	19
116	Mithramycin induces promoter reprogramming and differentiation of rhabdoid tumor. EMBO Molecular Medicine, 2021, 13, e12640.	3.3	7
117	Ribavirin as a potential therapeutic for atypical teratoid/rhabdoid tumors. Oncotarget, 2018, 9, 8054-8067.	0.8	15
118	Atypical Teratoid Rhabdoid Tumour : From Tumours to Therapies. Journal of Korean Neurosurgical Society, 2018, 61, 302-311.	0.5	31
119	Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. ELife, 2019, 8, .	2.8	32
120	Endogenous Retroelements and the Viral Mimicry Response in Cancer Therapy and Cellular Homeostasis. Cancer Discovery, 2021, 11, 2707-2725.	7.7	65
121	Atypical Teratoid Rhabdoid Tumours Are Susceptible to Panobinostat-Mediated Differentiation Therapy. Cancers, 2021, 13, 5145.	1.7	3
123	Embryonal Tumors: Atypical Teratoid/Rhabdoid Tumor (ATRT). , 2019, , 1643-1650.		1
124	Embryonale Tumoren. , 2019, , 573-592.		0
127	Rhabdoid Tumor, Soft Tissue. Encyclopedia of Pathology, 2020, , 1-9.	0.0	0
129	Atypical teratoid-rhabdoid tumors: molecular genetics features, perspectives of treatment. Review of literature. Russian Journal of Pediatric Hematology and Oncology, 2020, 7, 41-50.	0.1	0
130	Diverse outcomes in extra-cranial rhabdoid tumors: A single institute experience. Pediatric Hematology and Oncology, 2021, , 1-8.	0.3	0
131	Embryonal Tumors of the Central Nervous System: The WHO 2016 Classification and New Insights. Journal of Pediatric Hematology/Oncology, 2021, 43, 79-89.	0.3	2
132	Novel Two MRT Cell Lines Established from Multiple Sites of a Synchronous MRT Patient. Anticancer Research, 2020, 40, 6159-6170.	0.5	0
133	The epidemiology of primary and metastatic brain tumors in infancy through childhood. Journal of Neuro-Oncology, 2022, 156, 419-429.	1.4	6
135	Atypical teratoid rhabdoid tumor (ATRT): disease mechanisms and potential drug targets. Expert Opinion on Therapeutic Targets, 2022, 26, 187-192.	1.5	4
136	Evaluation and Diagnosis of Central Nervous System Embryonal Tumors (Non-Medulloblastoma). Pediatric and Developmental Pathology, 2022, 25, 34-45.	0.5	5
137	Epigenetic mechanisms in paediatric brain tumours: regulators lose control. Biochemical Society Transactions, 2022, 50, 167-185.	1.6	3



#	ARTICLE	IF	CITATIONS
138	Current and Emerging Therapeutic Approaches for Extracranial Malignant Rhabdoid Tumors. <i>Cancer Management and Research</i> , 2022, Volume 14, 479-498.	0.9	11
139	Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors. <i>International Journal of Oncology</i> , 2022, 60, .	1.4	4
141	Single-cell transcriptomics identifies potential cells of origin of MYC rhabdoid tumors. <i>Nature Communications</i> , 2022, 13, 1544.	5.8	9
142	Atypical Teratoid Rhabdoid Tumor: A Possible Oriented Female Pathology?. <i>Frontiers in Oncology</i> , 2022, 12, 854437.	1.3	4
143	Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 715-726.	1.9	11
145	Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care. <i>JCO Precision Oncology</i> , 2022, 6, e2100451.	1.5	3
146	ATRTâ€“SHH comprises three molecular subgroups with characteristic clinical and histopathological features and prognostic significance. <i>Acta Neuropathologica</i> , 2022, 143, 697-711.	3.9	13
147	Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumors. <i>Cell Death and Disease</i> , 2022, 13, 410.	2.7	4
148	Molecular targeted therapies for pediatric atypical teratoid/rhabdoid tumors. <i>Pediatric Investigation</i> , 2022, 6, 111-122.	0.6	3
149	Pediatric CNS cancer genomics and immunogenomics. <i>Current Opinion in Genetics and Development</i> , 2022, 75, 101918.	1.5	0
150	Bromodomain and Extra-Terminal Protein Inhibitors: Biologic Insights and Therapeutic Potential in Pediatric Brain Tumors. <i>Pharmaceuticals</i> , 2022, 15, 665.	1.7	5
151	The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors. <i>Nature Communications</i> , 2022, 13, .	5.8	16
152	Molecular Heterogeneity in Pediatric Malignant Rhabdoid Tumors in Patients With Multi-Organ Involvement. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
153	SMARCB1-Deficient Cancers: Novel Molecular Insights and Therapeutic Vulnerabilities. <i>Cancers</i> , 2022, 14, 3645.	1.7	18
154	Establishment and characterization of NCC-MRT1-C1: a novel cell line of malignant rhabdoid tumor. <i>Human Cell</i> , 0, , .	1.2	0
155	Primary cilia contribute to the aggressiveness of atypical teratoid/rhabdoid tumors. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	2
157	Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors. <i>Molecular Therapy - Oncolytics</i> , 2022, 27, 14-25.	2.0	10
158	Inherited Genetics Syndromes Associated with Central Nervous System Tumors. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
159	Molecular genetics of paediatric brain tumours and opportunities for precision medicine – a focus on infant tumours. <i>Current Opinion in Neurology</i> , 2022, 35, 772-778.	1.8	1
160	Artificial intelligence platform, RADRA® <sup>®</sup> , aids in the discovery of DNA damaging agent for the ultra-rare cancer Atypical Teratoid Rhabdoid Tumors. <i>Frontiers in Drug Discovery</i> , 0, 2, .	1.1	2
161	Pediatric Brain Tumors in the Molecular Era: Updates for the Radiologist. <i>Seminars in Roentgenology</i> , 2023, 58, 47-66.	0.2	3
162	Clustered regularly interspaced short palindromic repeats screens in pediatric tumours: A review. <i>Clinical and Translational Discovery</i> , 2022, 2, .	0.2	0
163	Atypical Teratoid/Rhabdoid Tumor of the Sellar Region in an Adult Male: A Case Report. <i>Cureus</i> , 2023, , .	0.2	0
164	Recent progress and novel approaches to treating atypical teratoid rhabdoid tumor. <i>Neoplasia</i> , 2023, 37, 100880.	2.3	5
165	Pediatric brain tumors: A neuropathologist's approach to the integrated diagnosis. <i>Frontiers in Pediatrics</i> , 0, 11, .	0.9	0
166	Diagnostic classification of childhood cancer using multiscale transcriptomics. <i>Nature Medicine</i> , 2023, 29, 656-666.	15.2	6
167	Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities. <i>Cancer Cell</i> , 2023, 41, 660-677.e7.	7.7	7
168	Atypical teratoid/rhabdoid tumoroids reveal subgroup-specific drug vulnerabilities. <i>Oncogene</i> , 2023, 42, 1661-1671.	2.6	5
169	Comparative treatment results of children with atypical teratoid/rhabdoid tumor of the central nervous system in the younger age group. <i>Russian Journal of Pediatric Hematology and Oncology</i> , 2023, 10, 11-24.	0.1	1
174	Embryonal Tumors of the Central Nervous System with Multilayered Rosettes and Atypical Teratoid/Rhabdoid Tumors. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 225-252.	0.8	0
177	Medulloblastomas, CNS embryonal tumors, and cerebellar mutism syndrome: advances in care and future directions. <i>Child's Nervous System</i> , 0, , .	0.6	0
184	Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	7